石杉碱甲类似物的研究II.N-甲基吡啶酮石杉碱甲类似物的合成

石杉碱甲(1)是从中草药石杉属植物千层塔(Lycopodium serratum Thunb.)中分得的一种高效可逆的乙酰胆碱酯酶抑制剂,临床试验证实它对早老性痴呆症有显著疗效。本文报道N-甲基吡啶酮石杉碱甲类似物2和3的合成。2-甲氧基-5-甲氧羰基-11-亚甲基-5,9-甲撑环辛-7-烯并吡啶(9)在乙腈中用三甲基氯硅烷和碘化钠选择性脱保护以定量的产率得吡啶酮10,再用甲醇钠和碘甲烷甲基化得N-甲基吡啶酮11,11经碱性水解,Curtius重排和氨基的脱保护得N-甲基吡啶酮石杉碱甲类似物2。通过类似的途径从中间体2-甲氧基-5-甲氧羰基-7-甲基-11-酮-5,9-甲撑环辛-7-烯并吡啶(14)合成了类似物3。类似物2和3的乙酰胆碱酯酶抑制活性均低于天然石杉碱甲。     

哇巴因与地高辛对大鼠心肌钠泵α亚单位基因表达影响的对比研究

目的　对比研究哇巴因与地高辛对大鼠心肌钠泵 (Na ,K ATP酶 )亚单位基因表达的影响 ,探讨内源性哇巴因(EO)的生物学效应以及洋地黄类药物药理作用的分子机制。方法　每天给予大鼠注射小剂量哇巴因 (2 0 μg·kg 1·d 1)与地高辛 (32 μg·kg 1·d 1) ,每周测量一次大鼠血压 ;6周后处死动物 ,应用RT PCR技术在mRNA水平探讨大鼠心肌钠泵α1、α2 及α3亚单位基因表达的改变。结果　给予大鼠注射哇巴因 6周后血压明显升高 (132 6± 9 0mmHgvs 115 7± 8 2mmHg ,P <0 0 1) ,而地高辛组大鼠血压与对照组比较无明显差异。哇巴因与地高辛均可导致大鼠心肌钠泵α亚单位基因表达的改变 :两者均可引起钠泵α3亚单位表达增强 ,而对α2 亚单位表达无影响 ;哇巴因组大鼠心肌钠泵α1亚单位表达减弱 ,而地高辛组α1亚单位表达无改变。结论　哇巴因与地高辛可导致不同的钠泵基因表达改变 ,这可能是内源性哇巴因发挥生理作用的分子机制之一 ,并且可能是哇巴因与地高辛药理及毒理作用 (包括两者对血压的调节 )不同的重要原因。     

胰腺癌组织VEGF和MVD表达与CT灌注成像的关系

血管内皮生长因子作为肿瘤血管生成的一种主要调控因子,与微血管密度密切相关．胰腺癌组织的血管内皮生长因子和微血管密度的测定对于判断患者的预后,指导临床治疗和判断疗效等具有重要作用．CT灌注成像可以通过无创伤检查反映胰腺癌的肿瘤血管构成, 在治疗前后提供有价值依据,对胰腺癌的诊治有重要意义．     

微型钛螺钉内固定加脱钙人牙基质材料促进陈旧性经舟月骨周围脱位的恢复疗效

目的:观察脱钙人牙基质材料与骨科植入物内固定治疗促进陈旧性经舟月骨周围脱位恢复的效果,并经远期随访。方法:选择1996-01/2005-10武汉市普爱医院8例陈旧性经舟月骨周围脱位病例,采用复位后微型钛螺钉内固定加脱钙人牙基质材料植入治疗。术后随访8周至3年。患者腕部功能采用Maya Modified Wrist Score法进行评估,优秀为91～100分;良好为80～90分;尚可为65～79分;差为<64分。结果:8例陈旧性经舟月骨周围脱位的舟骨骨折全部骨性愈合。优秀2例,良好3例,尚可2例,差1例。结论:微型钛螺钉内固定加脱钙人牙基质材料植骨操作简单,提高骨折愈合率,促进腕关节功能恢复,是促进陈旧性经舟月骨周围脱位恢复的一种有效方法。     

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.

PURPOSE: Interferon (IFN)-alpha2b is the only Food and Drug Administration-approved treatment for operable high-risk melanoma that has been shown to significantly and durably prolong relapse-free survival (RFS) of patients with stage IIB-III melanoma. Development of reliable serum assays may contribute to the development of methods for earlier detection of melanoma and the selection of patients who may be most susceptible to current available interventions with IFNalpha. EXPERIMENTAL DESIGN: A powerful high-throughput xMAP multiplex immunobead assay technology (Luminex Corp., Austin, TX) was used to simultaneously test 29 cytokines, chemokines, angiogenic as well as growth factors, and soluble receptors in the sera of 179 patients with high-risk melanoma and 378 healthy individuals. RESULTS: Serum concentrations of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-8, IL-12p40, IL-13, granulocyte colony-stimulating factor, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, IFNalpha, tumor necrosis factor (TNF)-alpha, epidermal growth factor, vascular endothelial growth factor (VEGF), and TNF receptor II were found to be significantly higher in patients with resected high-risk melanoma compared with healthy controls. Bayesian Network algorithm classification of the data offered 90% sensitivity at 98% specificity with 96.5% of melanoma patients distinguished from healthy individuals. IFN-alpha2b therapy resulted in a significant decrease of serum levels of immunosuppressive and tumor angiogenic/growth stimulatory factors (VEGF, epidermal growth factor, and hepatocyte growth factor) and increased levels of antiangiogenic IFN-gamma inducible protein 10 (IP-10) and IFN-alpha. Pretreatment levels of proinflammatory cytokines IL-1beta, IL-1alpha, IL-6, TNF-alpha, and chemokines MIP-1alpha and MIP-1beta were found to be significantly higher in the serum of patients with longer RFS values of 1 to 5 and >5 years when compared with patients with shorter RFS of <1 year. CONCLUSION: These data show that multiplexed analysis of serum biomarkers is useful for the evaluation of prognostic markers of clinical outcome and potential predictive markers of response to IFN-alpha2b in patients with high-risk operable melanoma.